Forventes på lager: 26-08-2009
Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation.
| Forlag | John Wiley & Sons Inc |
| Forfattere | Filip (Johnson & Johnson Pharmaceuticals Mussen, Sam (Cardiff University Salek, Stuart (CMR International Institute for Regulatory Science Walker |
| Type | Bog |
| Format | Hardback |
| Sprog | Engelsk |
| Udgivelsesdato | 26-08-2009 |
| Første udgivelsesår | 2009 |
| Originalsprog | United States |
| Sideantal | 304 |
| Indbinding | Hardback |
| Forlag | John Wiley & Sons Inc |
| Sideoplysninger | 304 pages |
| Mål | 174 x 253 x 22 |
| ISBN-13 / EAN-13 | 9780470060858 |